Clinical Trial Update: Efficacy and Safety of FP-1201-lyo (Interferon Beta-1a) in Patients Having Acute Respiratory Distress Syndrome (ARDS) [Phase 3]

View source ↗

Summary

Phase 3 trial of FP-1201-lyo (Interferon Beta-1a) in adults with acute respiratory distress syndrome was terminated; results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Distress Syndrome

Drugs mentioned

• FP-1201-lyo (Interferon Beta-1a)

Snippet

Sponsor: Faron Pharmaceuticals Ltd | Conditions: Respiratory Distress Syndrome, Adult | Phase 3 | Status: TERMINATED | Results posted: 2020-03-30